Kalaris Therapeutics Reports $10.9 Million Net Loss in Q1 2026 Amid Increased R&D Expenses

Kalaris Therapeutics, Inc. reported a net loss of $10.9 million for the first quarter of 2026, a slight increase from the $10.2 million loss recorded in the same period of 2025. The company's total operating expenses rose to $11.8 million, up from $10.4 million year-over-year, primarily driven by increased research and development costs associated with its lead product candidate, TH103. Research and development expenses increased by $1.5 million to $7.6 million, reflecting ongoing clinical trials and related activities. General and administrative expenses remained relatively stable at $4.3 million.

The company’s cash position has significantly changed, with cash and cash equivalents decreasing to $34.4 million as of March 31, 2026, down from $98.1 million at the end of 2025. This decline is attributed to cash used in operating activities, which totaled $11.6 million for the quarter, and substantial investments in marketable securities amounting to $70.4 million. Kalaris also reported a total of $104.9 million in cash, cash equivalents, and marketable securities, which management believes will be sufficient to fund operations into the fourth quarter of 2027.

Kalaris has undergone significant organizational changes following its merger with AlloVir, which was completed on March 18, 2025. The merger has positioned Kalaris as a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. The company is currently conducting a Phase 1b/2 clinical trial for TH103, which is designed to evaluate multiple dose levels in patients with neovascular age-related macular degeneration (nAMD). The trial is expected to provide preliminary data in the first half of 2027, with plans to expand TH103's development into other retinal diseases.

The company has also recognized a royalty obligation of $32.1 million to Samsara BioCapital under a related party agreement, which is contingent on future product sales. Kalaris continues to rely on external funding sources, including the recent $50 million raised through a private placement in December 2025. The company is actively exploring additional financing options to support its ongoing operations and product development efforts, as it has not yet generated revenue from product sales.

Looking ahead, Kalaris anticipates continued significant losses as it progresses through clinical trials and seeks regulatory approvals for TH103. The company emphasizes the need for substantial additional funding to sustain its operations and achieve its business objectives, which may include further clinical trials and potential commercialization efforts.